Conjugated estrogens/bazedoxifene

Drug Profile

Conjugated estrogens/bazedoxifene

Alternative Names: Aprela; Bazedoxifene acetate/conjugated estrogens; Bazedoxifene/conjugated estrogens; Bazedoxifene/Premarin®; BZA/CE; CE/BZA; Conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin®/bazedoxifene; SERM + Premarin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals; Wyeth
  • Developer Merck Sharp & Dohme; National Cancer Institute (USA); Northwestern University; Pfizer
  • Class Calcium regulators; Estradiol congeners; Hormonal replacements; Indoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Atrophic vaginitis; Postmenopausal osteoporosis; Vasomotor symptoms
  • Phase II Breast cancer

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Breast cancer (Newly diagnosed) in USA (PO) (NCT02694809)
  • 09 Dec 2016 The Scottish Medicines Consortium did not recommend conjugated estrogens/ bazedoxifene for use in NHS Scotland for the treatment of Atrophic vaginitis
  • 30 Aug 2016 Launched for Atrophic vaginitis in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top